Institutional Biosafety Committee Member Training

1. October 2014 Institutional Biosafety Committee Member Training

2. Background • Recombinant DNA work covered under NIH Office of Biotechnology Activities (NIH OBA) in: • NIH GUIDELINES FOR RESEARCH INVOLVING • RECOMBINANT OR SYNTHETIC NUCLEIC ACID MOLECULES (March 2013) • Purpose of Guidelines: • specify the practices for constructing and handling: • (i) recombinant nucleic acid molecules, • (ii) synthetic nucleic acid molecules, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules, • (iii) cells, organisms, and viruses containing such molecules.

3. IBC • Institutional Biosafety Committee (IBC) • Reviews all research that involves the use of rDNA • NIH/OBA rDNA Guidelines as reference document • Reviews research involving the use of infectious agents NOT rDNA • Inclusive of subcommittees-needlestick and healthcare • BMBL as a reference document

4. Biosafety Levels • Biosafety levels are a combination of facilities, equipment and practices. • Level 1: basic lab, good lab practices • Level 2: limited lab access, specific training and practices • Level 3: containment (biosafety cabinet), specific training and practices • Level 4: full containment; specific facility, training and practices

5. Risk Assessment Factors • Pathogenicity • Route of Transmission • Agent Stability • Infectious Dose • Concentration • Availability of effective prophylaxis, treatment • Availability of medical surveillance • Host susceptibility

6. Risk Assessment • Organism • Hosts • Vector • Expression of foreign gene • Protein produced • Containment • Facility • Laboratory-specific protocol • Training & expertise of personnel

7. History of the Guidelines The NIH Guidelines were implemented in response to public and scientific concern over the emerging science of rDNA technologies in the early 1970’s. By 1976, NIH had published the first set of guidelines which have been amended over time to allow for greater public access and a greater emphasis on safety.

8. Section I: Scope and Applicability • If your institution receives NIH funding for rDNA research, then it must comply with the NIH Guidelines. • Even if a project is privately sponsored, that research must still be conducted in accordance with the NIH Guidelines if conducted at an institution subject to the NIH Guidelines.

9. Section II: Safety Considerations Risk Assessment • Risk Group 1 (RG1) agents are not associated with disease in healthy adult humans. • Risk Group 2 (RG2) agents are associated with human disease which is rarely serious and for which preventive or therapeutic interventions are often available. • Risk Group 3 (RG3) agents are associated with serious or lethal human disease for which preventive or therapeutic interventions may be available. • Risk Group 4 (RG4) agents are likely to cause serious or lethal human disease for which preventive or therapeutic interventions are not usually available .

10. Section II: Safety Considerations Containment • Containment should be a combination of standard microbiology practices, engineering controls, laboratory facilities and design. • Containment is defined in: • Appendices G, P, & Q of the NIH Guidelines • Laboratory Safety Monograph (historical document) • Biosafety in Microbiological and Biomedical Laboratories (BMBL)

11. Section III: Experiments covered by the NIH Guidelines • III-A: transfer of drug resistance • III-B: cloning of lethal toxins • III-C: human gene transfer research • III-D: infectious agents as vectors & transgenic animals • III-E: generation of transgenic rodents • III-F: exemptions

12. Experiments Covered by the NIH

13. III-A: Major Actions • Requires: IBC Approval, RAC Review, NIH Director Approval Before Initiation of Work • Transfer of therapeutically useful drug resistance to organisms which may compromise human health/agriculture/medicine

14. III-B: Toxin Transfer • Requires: NIH/OBA, IBC Review and Approval Before Initiation of Work • Deliberate cloning of toxin molecules lethal to vertebrates at an LD50 of less than 100 nanograms/Kg of body weight (e.g., botulinum toxin) • Containment determined by NIH/OBA

15. III-C: (Deliberate Transfer of rDNA into Research Participants, ex. Gene Therapy) • Requires: RAC Review, IBC and IRB Approval Before Participant Enrollment • Human gene transfer (HGT) protocols • All HGT trials except those covered under vaccine exemption require RAC registration. • 20-30% will be publicly reviewed and may require public review prior to participant enrollment.

16. III-D: General Work • Requires: IBC Review and Approval Prior to the Initiation of Work • Involves RG 2-4 agents, host/vector system • Cloned DNA from RG 2-4 agents into non-pathogenic prokaryotes • RG 2-4 agents into whole animals, usually transgenic • Recombinant plants • Large scale experiments greater than 10L • Generation of any transgenic animal other than BSL-1 rodents

17. III-E: Less Restrictive Work • Requires: IBC Notification at the Initiation of Work (BSL-1 Containment), and Subsequent IBC Review and Approval • rDNA molecules that contains less than 2/3 of any eukaryotic viral genome • Transgenic rodents with BSL-1 containment • (crossbreeding of transgenics now exempt at BSL-1) • Whole plants that require minimal containment • Anything else NOT covered under sections III-A through III-D & III-F

18. III-F: Exemptions • Exempt from the NIH Guidelines and Does Not Require IBC Review or Approval • rDNA molecules that are: • Not in organisms or viruses • Not a risk to health or the environment • -See Appendix C • Note: exceptions to exemptions!

19. FAQ • Review process for human gene transfer protocols • http://osp.od.nih.gov/office-biotechnology-activities/biomedical-technology-assessment/hgt • Vaccine exemptions • http://osp.od.nih.gov/faq/faqs-about-vaccine-exemption-nih-guidelines-research-involving-recombinant-dna-molecules • Major actions under the guidelines • http://osp.od.nih.gov/sites/default/files/resources/Major_Action_FAQs_March_2013.pdf • Transgenic animals • http://osp.od.nih.gov/sites/default/files/Animals_NA_0.pdf

20. FAQ • IBC committee minutes • http://osp.od.nih.gov/sites/default/files/resources/IBC_Meetings_and_Minutes_FAQs.pdf • Experiments that are exempt • http://osp.od.nih.gov/sites/default/files/Experiments_that_are_Exempt_from_the_NIH_Guidelines.pdf

21. Section IV: Roles and Responsibilities • Responsibilities of the Institution: • Ensure compliance with NIH Guidelines • Establish IBC • Appoint a Biosafety Officer if conducting BSL-3, BSL-4, or large-scale work • Ensure IBC has expertise in the research that is reviewed • Establish a medical surveillance program as needed • Report all incidents to the NIH OBA

22. Section IV: Roles and Responsibilities Responsibilities of the IBC: • Review rDNA research, and approve those research projects that are found to conform with the NIH Guidelines. This review shall include: • -(i) independent assessment of the containment levels required by the NIH Guidelines for the proposed research; (ii) assessment of the facilities, procedures, practices, and training and expertise of personnel involved in rDNA research; (iii) ensuring that all aspects of Appendix M have been appropriately addressed by the PI; (vii) ensuring compliance with all surveillance, data reporting, and adverse event reporting requirements set forth in the NIH Guidelines. • Notify the PI of the results of the IBC’s review and approval. • Lower containment levels for certain experiments as specified in Section III-D-2-a, Experiments in which DNA from Risk Group 2, Risk Group 3, Risk Group 4, or Restricted Agents is Cloned into Nonpathogenic Prokaryotic or Lower Eukaryotic Host-Vector Systems. • Set containment levels as specified in Sections III-D-4-b, Experiments Involving Whole Animals.

23. Section IV: Roles and Responsibilities Responsibilities of the IBC: • Periodically review rDNA research conducted at the institution to ensure compliance with the NIH Guidelines. • Adopt emergency plans covering accidental spills and personnel contamination resulting from rDNA research. • Report any significant problems with or violations of the NIH Guidelines and any significant research-related accidents or illnesses to the appropriate institutional official and NIH/OBA within 30 days. • The IBC may notauthorize initiation of experiments which are not explicitly covered by the NIH Guidelines until NIH establishes the containment requirement.  • Perform such other functions as may be delegated to the IBC.

24. Section IV: Roles and Responsibilities Responsibilities of the Biological Safety Officer (BSO) • Periodic inspections to ensure that laboratory standards are rigorously followed;  • Report to the IBC and the institution any significant problems, violations of the NIH Guidelines, and any significant research-related accidents or illnesses of which the BSO becomes aware;  • Develop emergency plans for handling accidental spills and personnel contamination and investigating laboratory accidents involving rDNA research;  • Provide advice on laboratory security;  • Provide technical advice to PIs and the IBC on research safety procedures.

25. Section IV: Roles and Responsibilities Responsibilities of the Principal Investigator (PI) • Initiate or modify no recombinant DNA research which requires IBC approval prior to initiation until that research or the proposed modification thereof has been approved by the IBC and has met all other requirements of the NIH Guidelines;  • Determine whether experiments are covered by Section III-E, and ensure that the appropriate procedures are followed;  • Report any significant problems, violations of the NIH Guidelines, or any significant research-related accidents and illnesses to the BSO, Animal Facility Director (where applicable), IBC, NIH/OBA, and other appropriate authorities (if applicable) within 30 days;   • Report any new information bearing on the NIH Guidelines to the Institutional Biosafety Committee and to NIH/OBA   • Be adequately trained in good microbiological techniques;  • Adhere to IBC approved emergency plans for handling accidental spills and personnel contamination;   • Comply with shipping requirements for rDNA molecules.

26. Section IV: Roles and Responsibilities Responsibilities of the PI: • Responsible for full compliance with the NIH Guidelines in the conduct of rDNA research. • Responsible for ensuring that the reporting requirements are fulfilled and will be held accountable for any reporting lapses. • Prior to initiating research: • -Make available to all laboratory staff the protocols that describe the potential biohazards and the precautions to be taken;  • -Instruct and train laboratory staff in: (i) the practices and techniques required to ensure safety, and (ii) the procedures for dealing with accidents; and  • -Inform the laboratory staff of the reasons and provisions for any precautionary medical practices advised or requested (e.g., vaccinations).

27. Section IV: Roles and Responsibilities Responsibilities of the PI: • During conduct of research: • Supervise the safety performance of the laboratory staff to ensure that the required safety practices and techniques are employed;  • Investigate and report any significant problems pertaining to the operation and implementation of containment practices and procedures in writing to the BSO, Animal Facility Director (where applicable), IBC, NIH/OBA, and other appropriate authorities (if applicable) • Correct work errors and conditions that may result in the release of rDNA materials; and • Ensure the integrity of the physical containment (e.g., biological safety cabinets) and the biological containment (e.g., purity and genotypic and phenotypic characteristics).

28. IBC Requirements No fewer than 5 members who exhibit: • Required to annually submit IBC roster update including curriculum vitae of new members, brief biographical sketch and any significant updates of existing members to OBA

29. Dual Use • Consider dual use if any agents/toxins from the below list: • a) Avian influenza virus (highly pathogenic) • b) Bacillus anthracis • c) Botulinum neurotoxin • d) Burkholderia mallei • e) Burkholderiapseudomallei • f) Ebola virus • g) Foot-and-mouth disease virus • h) Francisellatularensis • i) Marburg virus • j) Reconstructed 1918 Influenza virus • k) Rinderpest virus • l) Toxin-producing strains of Clostridium botulinum • m) Variola major virus • n) Variola minor virus • o) Yersinia pestis

30. Dual Use Consider dual use if any agents/toxins from the previous listare used in the below categories of experiments: a) Enhances the harmful consequences of the agent or toxin b) Disrupts immunity or the effectiveness of an immunization against the agent or toxin without clinical and/or agricultural justification c) Confers to the agent or toxin resistance to clinically and/or agriculturally useful prophylactic or therapeutic interventions against that agent or toxin or facilitates their ability to evade detection methodologies d) Increases the stability, transmissibility, or the ability to disseminate the agent or toxin e) Alters the host range or tropism of the agent or toxin f) Enhances the susceptibility of a host population to the agent or toxin g) Generates or reconstitutes an eradicated or extinct agent or toxin listed in 6.2.1

31. UTHealth IBC Membership • Full Members • Serve staggered two year terms (FY 14-16) • 3+ faculty members with rDNA experience and/or biological safety and containment • 2 individuals not associated with the institution (community member) • At least 1 member from each school • At least 1 with animal containment • At least 1 with infectious disease expertise • 1 student member • Ex-Officio Members • Representative from Risk Management/Legal Affairs • Representative from Health Services • Director, Environmental Health & Safety • VP, SHERM • Executive Vice President for Research • Representative from HCPC

32. Expectations: Members • Active participation on the Committee • Sharing expertise and experience • Question and scrutinize protocols • Ensure protocols meet requirements of NIH Guidelines, BMBL and other biosafety guidelines • Participate as a member of a Subcommittee during preliminary reviews • Timely response as a member of a Subcommittee • Participate in member training, at least annually

33. UTHealth Protocol Review Submitted to Biosafety for assessment Communication with PI to produce protocol Submitted to Subcommittee for review Submit protocol to IBC for full review Protocol accepted Protocol rejected, tabled or pending

34. Approval Memos • Once a protocol is approved the appropriate memo is sent out • Approval memo • Conditional approval memo

35. Conditionally Exempt Protocols • To be a conditionally exempt protocol, proposed work must meet the following conditions: • No work that falls under the NIH Guidelines • Only involves the collection of human samples (i.e. blood, urine, tissue, etc.) • Sample processing limited to: • Centrifugation • Storage • Biological safety office reviews and approves protocols • Protocols appear in meeting packets

36. IBC Resources • NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules • http://osp.od.nih.gov/sites/default/files/NIH_Guidelines_0.pdf • Office of Biotechnology Activities • http://www4.od.nih.gov/oba/ • CDC/NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL) • http://www.cdc.gov/biosafety/publications/bmbl5/BMBL.pdf

37. Questions?